Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
  • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Definitions

• the present invention relates to variants of TY145 subtilases and BPN' subtilases and to methods of construction such variants with altered properties, such as stability (e.g. thermo- stability or storage stability), Ca 2+ dependency, pH dependent activity.
• stability e.g. thermo- stability or storage stability
• Ca 2+ dependency e.g. Ca 2+ dependency
• pH dependent activity e.g. thermo- stability or storage stability
• Enzymes have been used within the detergent industry as part of washing formulations for more than 30 years. Proteases are from a commercial perspective the most relevant enzyme in such formulations, but other enzymes including lipases, amylases, cellulases, hemicellu- lases or mixtures of enzymes are also often used.
• proteases with altered properties such as increased activity at low temperatures, increased thermostability, increased specific activity at a given pH, altered Ca 2+ dependency, increased stability in the presence of other detergent ingredients (e.g. bleach, surfactants etc.) etc.
• the search for proteases with altered properties include both discovery of naturally occurring proteases, i.e. so called wild-type proteases but also alteration of well-known proteases by e.g! genetic manipulation of the nucleic acid sequence encoding said proteases. Knowledge of the relationship between the three-dimensional structure and the function of a protein has improved the ability to evaluate which areas of a protein to alter to affect a specific characteristic of the protein.
• subtilases One family of proteases, which are often used in detergents, are the subtilases. This family has previously been further grouped into 6 different sub-groups by Siezen RJ and Leunissen JAM, 1997, Protein Science, 6, 501-523. One of these sub-groups is the Subtilisin family which includes subtilases such as BPN', subtilisin 309 (SAVINASE ® , NOVOZYMES A/S), subtilisin Carlsberg (ALCALASE ® NOVOZYMES A/S), subtilisin S41 (a subtilase from the psychrophilic Antarctic Bacillus TA41 , Davail S et al. 1994, The Journal of Biological Chemistry, 269(26), 99.
• subtilases such as BPN', subtilisin 309 (SAVINASE ® , NOVOZYMES A/S), subtilisin Carlsberg (ALCALASE ® NOVOZYMES A/S), subtilisin S41 (a subtilase from the psych
• subtilisin S39 a subtilase from the psychrophilic Antarctic Bacillus TA39, Narinx E et al. 1997, Protein Engineering, 10 (11), pp. 1271-1279
• TY145 a subtilase from Bacillus sp. TY145, NCIMB 40339 described in WO 92/17577.
• modelling of the three-dimensional structure of one subtilase on the basis of the three-dimensional structure of another subtilase may result in an incorrect three- dimensional structure because of structural differences.
• the inventors of the present invention have elucidated the three-dimensional structure of the TY 45 subtilase and found that there are several differences between this and the three- dimensional structure of BPN' also belonging to the Subtilisin subgroup of subtilases.
• This surprising difference in structure makes it advantageous to use the TY145 structure as basis for homology modelling of TY145 like subtilisins, which, in turn, will improve the ability to obtain desired changes in functionality by protein engineering.
• Mi- yazaki K et al. 2000, J Mol Biol, 297, pp.1015-1026 discloses enhancement of the thermostability and activity of the psychrophilic protease subtilisin S41 by methods of directed evolution.
• Wintrode TL et al. 2000, Journal of Biological Chemistry, 275 (41), pp.31635-31640 discloses conversion of a mesophilic subtilisin-like protease from Bacillus sphaericus SSI I into its psy- chrophilic counterpart by methods of directed evolution.
• Wintrode et al. constructed the three-dimensional structural model of the SSII subtilase on basis of its homology with subtilisins Carlsberg, Savinase, BPN' and Thermitase.
• the SSII subtilase pertain to the new group of TY145 like subtilases and thus the modelling of SSII based on the 3D structure of the BPN' like subtilases will likely give an inaccurate result.
• the inventors have modified the amino acid sequence of a subtilase to obtain variants with improved properties, based on the three-dimensional structure of the subtilases TY145 and BPN'.
• the variants have altered properties, such as increased activity at low temperatures, increased thermostability, increased specific activity at a given pH, altered Ca 2+ dependency, increased stability in the presence of other detergent ingredients (e.g. bleach, surfactants etc.) etc.
• the object of the present invention is to provide a method for constructing subtilases having altered properties, in particular to provide a method for constructing subtilases having altered properties as described above.
• the present invention relates to a method for constructing a variant of a parent subtilase, wherein the variant has at least one altered property as compared to said parent subtilase, which method comprises: i) analyzing the three-dimensional structure of the subtilase to identify, on the basis of an evaluation of structural considerations, at least one amino acid residue or at least one structural region of the subtilase, which is of relevance for altering said property; ii) constructing a variant of the subtilase, which as compared to the parent subtilase, has been modified in the amino acid residue or structural part identified in i) so as to alter said property; and iii) testing the resulting subtilase variant for said property.
• modification of the parent subtilase in certain regions and/or positions is expected to confer a particular effect to the thus produced subtilase variant
• modification of the parent subtilase in any of such regions may also give rise to any other of the above-mentioned effects.
• any of the regions and/or positions mentioned as being of particular interest with respect to, e.g., improved thermostability may also give rise to, e.g., higher activity at a lower pH, an altered pH optimum, or increased specific activity, such as increased peptidase activity.
• APPENDIX 1 shows the structural coordinates for the solved crystal 3D structure of the TY145 subtilase.
• Figure 1 shows a multiple alignment of 3D sequences of subtilases from TY145, TA39,
• Figure 2 shows an alignment between the amino acid sequences of subtilisin BPN' and Savinase in order to define the BPN' numbering of Savinase.
• Figure 3 shows a superposition of TY145 subtilase (light) and BPN' structures (dark), with spheres indicating ion-binding sites.
• the TY145 ion-binding sites are light and the BPN' ion- binding sites are dark.
• Serine proteases or serine peptidases is a subgroup of proteases characterised by having a serine in the active site, which forms a covalent adduct with the substrate. Further the subtilases (and the serine proteases) are characterised by having two active site amino acid residues apart from the serine, namely a histidine and an aspartic acid residue. Subtilases are defined by homology analysis of more than 170 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases. The subtilases may be divided into 6 sub-divisions, i.e. the Subtilisin family, the Thermitase family, the Proteinase K family, the Lantibiotic peptidase family, the Kexin family and the Pyrolysin family.
• subtilisin family (EC 3.4.21.62) may be further divided into 3 sub-groups, i.e. I-S1 ("true" subtilisins), I-S2 (highly alkaline proteases) and intracellular subtilisins. Definitions or grouping of enzymes may vary or change, however, in the context of the present invention the above division of subtilases into sub-division or sub-groups shall be understood as those de- scribed by Siezen et al., Protein Engng. 4 (1991) 719-737 and Siezen et al. Protein Science 6 (1997) 501-523.
• parent is in the context of the present invention to be understood as a protein, which is modified to create a protein variant.
• the parent protein may be a naturally occurring (wild-type) polypeptide or it may be a variant thereof prepared by any suitable means.
• the parent protein may be a variant of a naturally occurring protein which has been modified by substitution, chemical modification, deletion or truncation of one or more amino acid residues, or by addition or insertion of one or more amino acid residues to the amino acid sequence, of a naturally-occurring polypeptide.
• parent subtilase refers to a subtilase which is modified to create a subtilase variant.
• variant is in the context of the present invention to be understood as a protein which has been modified as compared to a parent protein at one or more amino acid residues.
• modification(s) or “modified” is in the context of the present invention to be understood as to include chemical modification of a protein as well as genetic manipulation of the DNA encoding a protein.
• the modification(s) may be replacement(s) of the amino acid side chain(s), substitution(s), deletion(s) and/or insertions in or at the amino acid(s) of interest.
• modified protein e.g. "modified subtilase”
• subtilase is to be understood as a protein which contains modification(s) compared to a parent protein, e.g. subtilase.
• subtilase or "(a) TY145 like subtilase” should in the context of the pre- sent invention be understood as a subtilase belonging to the Subtilisin group according to Siezen et al. Protein Science 6 (1997) 501-523 and which has at least 63% homology to TY145, SEQ ID NO:1. In the context of the present invention a TY145 subtilase has three ion-binding sites.
• subtilase or "(a) BPN' like subtilase” should in the context of the present invention be understood as a subtilase belonging to the Subtilisin group according Siezen et al. Siezen et al. Protein Science 6 (1997) 501-523 and which has at least 61% homology to BPN' SEQ ID NO:5.
• Such a BPN' like subtilase is for example Savinase.
• a BPN 1 subtilase has two, three or five ion-binding sites.
• a BPN' like subtilase may, in the context of the present invention, belong to branch l-S of the subtilisins i.e. to branch I-S1, the "true” subtilisins or I-S2, the highly alkaline proteases (Siezen et al., Protein Engng. 4 (1991) 719-737).
• Identities can be extracted from the same calculation.
• the output from the routine is besides the amino acid alignment the calculation of the "Percent Identity" and the "Similarity” between the two sequences.
• the numbers calculated using UWGCG package version 9.1 is slightly different from the version 8.
• position is in the context of the present invention to be understood as the number of an amino acid in a peptide or polypeptide when counting from the N-terminal end of said peptide/polypeptide.
• position numbers used in the present invention refer to different subtilases depending on which subgroup the subtilase belongs to.
• subtilases belonging to the TY145 subgroup i.e. subtilases obtained from TY145, TA39, TA41 and Bacillus sphaericus are numbered individually according to each of SEQ ID NO:1 ,2,3 and 4.
• subtilases belonging to the TY145 subgroup are numbered individually according to their own sequence. However in order to determine homologous positions in such other subtilases an alignment with each of SEQ ID's NO:1 ,2,3 and 4 is conducted according to the GAP procedure described above. Subsequently the homologous positions are determined with reference to the most homologous of SEQ ID's NO: 1 ,2,3 and 4. Alternatively subtilases belonging to the TY145 subgroup can be numbered by reference to the positions of TY145 subtilase (SEQ ID NO:1).
• Subtilases belonging to the BPN' subgroup refers to the positions of Subtilisin Novo (BPN') from B. amyloliquefaciens (SEQ ID NO:5).
• BPMES Bacillus pumilus
• the inventors of the present invention find that the subgroup of TY145 subtilases are different from BPN' subtilases based on the 3D structure comparison of the enclosed 3D structure of TY145 and the BPN' 3D structure but also indicated from the sequence homology between TY145 and BPN'.
• a TY145 subtilase is in the context of the present invention to be under- stood as a subtilase which has at least 63% homology to SEQ ID NO:1.
• said TY145 subtilase may have at least 65%, such as at least 70%, at least 74%, at least 80%, at least 83%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology to TY145, i.e. to SEQ ID NO:1.
• a TY145 subtilase suitable for the purpose described herein may be a subtilase homologous to the three-dimensional structure of TY145, i.e. it may be homologous to the three-dimensional structure defined by the structure coordinates in Appendix 1.
• a set of structure coordinates for a protein or a portion thereof is a relative set of points that define a shape in three dimensions, it is possible that an entirely different set of coordinates could define an identical or a similar shape.
• slight variations in the individual coordinates may have little or no effect on the overall shape.
• variations in coordinates may be generated because of mathematical manipulations of the structure coordinates.
• the structure coordinates of Appendix 1 (TY145 structure) may be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above.
• said variations may be due to differences in the primary amino acid sequence. If such variations are within an acceptable standard error as compared to the structure coor- dinates of Appendix 1 said three-dimensional structure is within the context of the present invention to be understood as being homologous to the structure of Appendix 1.
• the standard error may typically be measured as the root mean square deviation of e.g.
• RMS root mean square deviation
• similarities in 3D structure of different subtilases can be described by the content of homologous structural elements, and/or the similarity in amino acid or DNA sequence. For sequences having no deletions or insertions a RMS for the calcium atoms can be calculated.
• TY145 like subtilases examples include the psychrophilic subtilisin protease S41 derived from the Antarctic Bacillus TA41, herein also called TA41 subtilase (Davail S et al., 1994, J.
• subtilisin protease S39 derived from the Antarctic Bacillus TA39, herein also called TA39 subtilase (Narinx E et al., 1997, Protein Engineering, 10 (11), 1271-1279). Recently a three-dimensional structure of a subtilisin homologous with the TY145 subtilisins was published in the Protein Data Bank (Accession No:1EA7).
• a preferred embodiment of the present invention is a parent subtilase or a subtilase variant which is at least 63% homologous to the sequence of SEQ ID NO:1 , preferably at least 65%, at least 70%, at least 74%, at least 80%, at least 83%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homologous to the sequence of SEQ ID NO:1 , and optionally said subtilase further comprises the following structural characteristics: a) a twisted beta-sheet with 7 strands, b) six alpha helices, c) at least three ion-binding sites and wherein the Strong ion-binding site of the BPN' like subtilases is not present, and with the exception of the TY145 subtilase, the TA39 subtilase, the TA41 subtilase, and the Bacillus s
• the TY145 subtilase of the present invention is encoded by an isolated nucleic acid sequence, which nucleic acid sequence has at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology with the nucleic acid sequence shown in SEQ ID NO:20.
• isolated nucleic acid sequence encoding a TY145 subtilase of the invention hy- bridizes with a complementary strand of the nucleic acid sequence shown in SEQ ID NO:20 preferably under low stringency conditions, at least under medium stringency conditions, at least under medium/high stringency conditions, at least under high stringency conditions, at least under very high stringency conditions.
• Suitable experimental conditions for determining hybridization at *low, medium, or high stringency between a nucleotide probe and a homologous DNA or RNA sequence involves pre- soaking of the filter containing the DNA fragments or RNA to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 ⁇ g/ml of denatured sonicated salmon sperm DNA (Sambrook et al.
• the filter is then washed twice for 30 minutes in 2 x SSC, 0.5 % SDS at least * 55°C (low stringency), more preferably at least 60°C (medium stringency), still more preferably at least 65°C (medium/high stringency), even more preferably at least 70°C (high stringency), and even more preferably at least 75°C (very high stringency).
• a BPN' subtilase is in the context of the present invention to be understood as a subtilase which has at least 61% homology to SEQ ID NO:5.
• said BPN' subtilase may have at least 70%, such as at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology to BPN', i.e. to SEQ ID NO:5.
• a BPN' subtilase suitable for the purpose described herein may be a subtilase homologous to the three-dimensional structure of BPN'- as defined by the structure coordinates given, in PDB Nos. 1SBT and 1GNS (Protein Data Bank), or one of the several other structures of BPN' that are accessible from the Protein Data Bank. Variations between homologous structures may occur for several reasons as described above.
• a BPN' subtilase within the context of the present invention is to be understood as any subtilase having the structural characteristics pertaining to the BPN' subti- lases as described above, and in addition such subtilases does preferably not have further structural characteristics which are not present in the BPN 1 subtilases as described herein.
• a BPN' subtilase of the present invention may have the necessary percentage of similarity with SEQ ID NO:5.
• BPN' like subtilases examples include the subtilisin 309 (PDB NO:1SVN SAVINASE ® , NOVOZYMES A/S) and subtilisin Carlsberg (ALCALASE ® , NOVOZYMES A/S), among others.
• subtilase consists of 6-8 helices, 11 strands of which 7 are central in a twisted beta-sheet. Two ion-binding sites are mentioned, one of which is the so called "Weak" calcium-binding site. It was later discovered that for some structures (subtilisin DY PDB no. 1 BH6, 1998), this calcium-binding site was shown to be a Na (sodium) binding site when the calcium concentration in the crystallization medium was low. Thus, in the following we refer to ion-binding sites instead of calcium-binding sites.
• the BPN' subtilase of the present invention is encoded by an isolated nucleic acid sequence, which nucleic acid sequence has at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology with the nucleic acid sequence shown in SEQ ID NO:21.
• isolated nucleic acid sequence encoding a BPN' subtilase of the invention hybridizes with a complementary strand of the nucleic acid sequence shown in SEQ ID NO:21 preferably under low stringency conditions, but at least under medium stringency conditions, at least under medium/high stringency conditions, at least under high stringency conditions, at least under very high stringency conditions.
• the TY145 subtilase was used to elucidate the three-dimensional structure forming the basis for the present invention.
• the structure of TY145 was solved in accordance with the principle for x-ray crystallographic methods, for example, as given in X-Ray Structure Determination, Stout, G.K. and Jensen, L.H., John Wiley & Sons, Inc. NY, 1989.
• the structural coordinates for the solved crystal structure of TY145 are given in standard PDB format (Protein Data Bank, Brookhaven National Laboratory, Brookhaven, CT) as set forth in Appendix 1. It is to be understood that Appendix 1 forms part of the present application.
• CA refers to c-alpha (carbon atoms) or to calcium ions, (however to avoid misunderstandings we use the full names "c-alpha atoms” and “calcium” or “ion” in the present specification).
• Amino acid residues are given in their standard three-letter code.
• the attached structural coordinates contain the protease structure, and an inhibitor structure CI2 as well as water molecules.
• the protease coordinates has a chain identification called A, whereas the CI2 inhibitor is called B, the calcium ions are called C, and the water is W.
• the positions of the men- tioned residues refer to the sequence of TY145 as disclosed in SEQ ID NO:1.
• the structure of TY145 shows the same "overall" fold as found in the S8 family of subtilisins.
• the structure comprises a twisted beta-sheet with 7 strands arranged in the following sequential order S2, S3, S1 , S4, S5, S6, S7.
• the TY145 like subtilases are shown to lack the well-known Strong ion-binding site of the BPN' subtilases.
• the TY145 subtilases have two ion-binding sites which are not present in the BPN' subtilisin structures. This can be seen in the structural alignment presented in Figure 3. These additional ion-binding sites are hereinafter referred to as "Near” and “Far” according to their distance to the Weak ion-binding site.
• the ion-binding sites of TY145 are located at: Weak - calcium atom named C 314, Near - calcium atom named C 312, and Far - calcium atom named C 313 in the PDB table (Appendix 1).
• the position of an ion-binding site can be defined by the distance to four specific atoms in the core structure.
• the distance from the ion-binding site to the c-alpha atoms of the three active site residues has been chosen.
• the residues Ser, His and Asp in the active site are highly conserved. In TY145 they are Asp35, His72 and Ser251.
• the fourth distance chosen is the distance to the c-alpha atom of the amino acid residue coming first after the active site serine residue in the sequence (herein after called "next to Ser"); in the 3D structure of TY145 it is Met252. • .
• the distance between: a) the Weak ion-binding site and i) Asp c-alpha atom is 17.50-19.50A, ii) His c-alpha atom is 21-23A, iii) Ser c-alpha atom is 13.80-15.80A, iv) next to Ser c-alpha atom is 15.80-
• Ser c-alpha atom is 20-22A, iv) next to Ser c-alpha atom is 19.50-21.50A, c) the Near ion-binding site and i) Asp c-alpha atom is 27-29A, ii) His c-alpha atom is
• the distances may vary from one subtilase to the other, and as described above, the Weak ion binding site may also bind to a sodium ion.
• the present distances are given with a calcium ion in the structure. If a sodium ion was bound instead the distances would be shifted a little bit.
• the distances can vary ⁇ O. ⁇ A, preferably +0.7A, ⁇ 0.6A, ⁇ O. ⁇ A, ⁇ 0.4A, or most preferably ⁇ 0.3A.
• the peptide structure circumscribing the Weak ion- binding site is composed of the amino acid residues placed in positions 182-189 and 221- 227 with the coordinating atoms being the backbone carbonyl oxygen atom of residues G182, A187, L184 and two water molecules.
• the peptide structure circumscribing the Near ion-binding site is composed of residues 212- 225 with the coordinating atoms being the backbone carbonyl oxygen atom of residues I220 and T215, the oxygens from the carboxylic acids of residues D225 and D218 and the amid group of residue Q222.
• the peptide structure circumscribing the Far ion-binding site is composed of residues 288- 306 with the coordinating atoms being the backbone carbonyl oxygen atom of residues G298, G296 and I289, the oxygens from the carboxylic acids of residues D300 and D288, and two water molecules.
• the structure of the TY145 like subtilase can be divided into a "common subtilase-like" region, an "intermediate” region and a "non- homolo-gous" region.
• the active site can be found in the common subtilase-like region, which is structurally closely related to the BPN' structures.
• the common subtilase-like region is composed of residues 88-128 and 225-284, and contains the alpha-helix H3 and the central alpha-helix H5 in which the active site serine residue is situated in the N-terminal part.
• the common subtilase-like region has an RMS lower than 1.2.
• the structure of the TY145 like subtilase differs from the BPN' structures to a greater extent.
• the intermediate region consist of residues 24-45, 48-58, 65-66, 67-85, 134-174, 175-196, 202-212 and 287-290.
• the intermediate region has an RMS higher than 1.2 and lower than 1.8.
• the relationships between the three-dimensional structure and functionality are potentially difficult to predict in this region of the TY145 like subtilases.
• the nonhomologous region consists of residues 5-15, 16-23, 86-87, 129-133, 197-201 , 213-
• the nonhomologous region has a RMS higher than 1.5, which also pertains to residues 65-66 from the intermediate region.
• the group comprising residues 5-15 and 299-311 has an RMS between 2.1-2.2. The relationships between the three-dimensional structure and functionality are very difficult to predict in this region of the TY145 like subtilases.
• the regions in areas A1-T5, N16-T24, A46-Q51 , S58-C66, G84-G90, S129-K134, S129- K134, S173-S175, V196-T201 , N212-R224, A284-V286, K290-D299 and V310-K311 in the TY145 structure differs significantly from the other S8 family subtilisins (including the BPN 1 type subtilisins) in c-alpha atom coordinates. An RMS cannot be calculated for these last residues as there are no homologous c-alpha atoms in the compared subtilases.
• a model structure of a TY145 like subtilase or a BPN' like subtilase can be built using the Homology program or a comparable program, e.g., Modeller (both from Molecular Simulations, Inc., San Diego, CA).
• the principle is to align the amino acid sequence of a protein for which the 3D structure is known with the amino acid sequence of a protein for which a model 3D structure has to be constructed.
• the structurally conserved regions can then be built on the basis of consensus sequences.
• loop structures can be inserted, or sequences can be deleted with subsequent bonding of the necessary residues using, e.g., the program Homology. Subsequent relaxing and optimization of the structure should be done using either Homology. or another molecular simulation, program," e.g., CHARMm from Molecular Simulations.
• the present invention comprises a method of producing a variant of a parent TY145 like subtilase, the variant having at least one altered property as compared to the parent TY145 like subtilase, the method comprising: a) modelling the parent TY145 subtilase on the three-dimensional structure of a TY145 subtilase to produce a three-dimensional structure of the parent TY145 subtilase; b) comparing the three-dimensional structure obtained in step a) to the three-dimensional structure of a TY145 subtilase; c) identifying on the basis of the comparison in step b) at least one structural part of the parent TY145 subtilase, wherein an alteration in said structural part is predicted to result in an altered property; d) modifying the nucleic acid sequence encoding the parent TY145 subtilase to produce a nucleic acid sequence encoding deletion or substitution of one or more amino acids at a position corresponding to said structural part, or an insertion of one or more amino acid residues in positions
• subtilase TY145 subtilase; f) isolating the produced subtilase; g) purifying the isolated subtilase and h) recovering the purified subtilase.
• the present invention comprises a method of producing a variant of a parent Subtil- isin family subtilase, such as a BPN' like subtilase, the variant having at least one altered property as compared to the parent Subtilisin family subtilase, the method comprising: a) modelling the parent Subtilisin family subtilase on the three-dimensional structure of a Subtilisin family subtilase to produce a three-dimensional structure of the parent Subtilisin family subtilase; b) comparing the three-dimensional structure obtained in step a) to the three-dimensional structure of a TY145 like subtilase; c) identifying on the basis of the comparison in step b) at least one structural part of , the parent Subtilisin family subtilase, wherein an alteration in said structural part is predicted to result in an altered property; d) modifying the nucleic acid sequence encoding the parent Subtilisin family subtilase to produce a nucleic acid sequence en
• the present invention comprises a method of producing a variant of a parent TY145 like subtilase, the variant having at least one altered property as compared to the parent TY145 like subtilase, the method comprising: a) modelling the parent TY145 like subtilase on the three-dimensional structure of a TY145 like subtilase to produce a three-dimensional structure of the parent TY145 like subti- lase; b) comparing the three-dimensional structure obtained in step a) to the three-dimensional structure of a Subtilisin family subtilase; c) identifying on the basis of the comparison in step b) at least one structural part of the parent TY145 like subtilase, wherein an alteration in said structural part is predicted to result in an altered property; d) modifying the nucleic acid sequence encoding the parent TY145 like subtilase to produce a nucleic acid sequence encoding deletion or substitution of one or more amino ac- ids at a position corresponding to said
• the TY145 subtilases has two new ion-binding sites not present in the BPN' subtilisin structures but lacks the Strong ion-binding site of the BPN' subtilases. Stability of the ion-binding site is of crucial importance for the functionality of the enzyme. Therefore alterations of the amino acid residues close to the ion-binding sites are likely to result in alterations of the stability of the enzyme.
• the positions which may be modified are located: Weak: at a distance of 10A or less around calcium atom named C 314, Near: at a distance of 10A or less around calcium atom named C 312, and Far: at a distance of 10A or less around calcium atom named C 313 in the PDB table (Appendix 1).
• Stabilisation of the ion-binding sites of TY145 may possibly be obtained by alterations in the positions close to the sites. Positions located at a distance of 10A or less to the ion-binding sites of TY145 (SEQ ID NO:1) are:
• variants with improved calcium stability can be constructed.
• Variants with alterations close to the Near ion-binding site are I220S,T and T215S
• variants with alterations close to the Far ion-binding site are G298A,S,T and G296A,S,T
• variants with alterations close to the Weak ion-binding site are V185T and I221N,D,T.
• TY145 with extra ion-binding site The Strong ion-binding site from the BPN' subtilases can be transplanted into TY145 (or other subtilases in TY145 subgroup) by deletion(s) of or in the region H83-G90 (of SEQ ID NO:1) and subsequent insertion of one or more amino acid residues.
• a preferred variant has the whole region deleted and a subsequent insertion between A82 and V91 of the sequence LNNSIG.
• the Far and Near ion-binding sites in TY145 can be removed with guidance from the three-dimensional structure of BPN' and Sav-. inase (or others in BPN 1 group).
• Removal of the Far site can be done by deletion(s) of or in the region K290-D300 (of SEQ ID NO:1) and subsequent insertion of one or more amino acid residues.
• a preferred variant has the whole region deleted and a subsequent insertion between I289 and Y301 of the sequence GDS or DST.
• the substitution S303Y is further added.
• Removal of the Near site can be done by deletion(s) of or in the region N212-R224 (of SEQ ID NO:1) and subsequent insertion of one or more amino acid residues.
• a preferred variant has the whole region deleted and a subsequent insertion of a proline or alanine residue between G211 and D225.
• the Strong ion-binding site in BPN' like subtilases can be removed. Exemplified in Savinase, the removal can be done by deletion of or in the region L75-G80 (BPN' numbering) and subsequent insertion of one or more amino acid residues.
• a preferred variant has the whole re- gion deleted and a subsequent insertion of residues 84-88 from TY145.
• substitutions L82Y and Q2A,N can be applied. Alteration of thermostability
• a variant with improved stability may be obtained by substitution with proline, introduction of a disulfide bond, altering a hydrogen bond contact, altering charge distribution, introduction of a salt bridge, filling in an internal structural cavity with one or more amino acids with bulkier side groups (in e.g. regions which are structurally mobile), substitution of histidine residues with other amino acids, removal of a deamidation sites, or by helix capping.
• Regions with increased mobility The following regions of TY145 have an increased mobility in the crystal structure of the enzyme, and it is presently believed that these regions can be responsible for stability or activity of TY145. Especially thermostabilisation may possibly be obtained by altering the highly mobile regions. Improvements of the enzyme can be obtained by mutation in the below regions and positions. Introducing e.g. larger residues or residues having more atoms in the side chain could increase the stability, or, e.g., introduction of residues having fewer atoms in the side chain could be important for the mobility and thus the activity profile of the enzyme, The regions can be found by analysing the B-factors taken from the coordinate file in Appendix 1 , and/or from molecular dynamics calculations of the isotropic fluctuations. These can be obtained by using the program CHARMm from MSI (Molecular Simulations Inc.).
• 141-146 i.e. 141 , 142, 143, 144, 145, 146)
• 150-152 i.e.150, 151 , 152
• 169-171 i.e. 169, 170, 171 200-201
• 211-220 i.e. 211 , 212, 213, 214, 215, 216, 217, 218, 219, 220
• 242-243 268-270 i.e. 268, 269, 270.
• 38-50 i.e. 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50
• 57-69 i.e. 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69
• 84-92 i.e. 84, 85, 86, 87, 88, 89, 90, 91, 92
• 107-110 i.e. 107, 108, 109, 110
• 239-243 i.e. 239, 240, 241 , 242, 243
• 265-266 Preferably the regions 57-69 and 84-92.
• a TY145 variant of the present invention with improved stability, e.g. thermostability, as compared to the parent TY145 may be obtained by introducing new inter-domain or intra-domain bonds, such as by establishing inter- or intra-domain disulfide bridges.
• a further aspect of the present invention relates to a method for producing a variant of a parent TY145 comprising the methods described in the paragraph "Methods of preparing TY145 like or BPN' like subtilase variants" herein.
• amino acid residues iden ⁇ tified in the amino acid sequence of SEQ ID NO:1 are contemplated as being suitable for cysteine replacement.
• disulfide bridges may possibly form in a variant of TY145.
• the substitutions are: G26C+A95C; A167C+T254C; R203C+G292C and V228C+A284C:
• Similar residues suitable for cysteine replacement in homologous subtilases such as TA39, TA41 can be elucidated by finding the homologous positions in the alignment of Figure 1.
• Concerning another TY145 like sequence the homologous positions suitable for cysteine replacement can be selected by aligning said TY145 like sequence with all of the sequences of Figure 1 using the GAP analysis method as described above.
• the suitable residues can then be selected in accordance with the homologous positions in the most homologous of SEQ ID's NO:1 ,2,3 and 4 which are the sequences of the subtilases aligned in Figure 1.
• a variant with improved stability (typically improved thermostability) as compared to the parent subtilase may be obtained by changing the surface charge distribution of the subtilase. For example, when the pH is lowered to about 5 or below histidine residues typically become positively charged and, consequently, unfavorable electrostatic interactions on the protein surface may occur. By engineering the surface charge of the subtilase one may avoid such unfavorable electrostatic interactions that in turn lead to a higher stability of the subtilase.
• a further aspect of the present invention relates to a method for constructing a variant of a parent subtilase, the method comprising: a) identifying, on the surface of the parent subtilase, preferably a TY145 like or a BPN' like subtilase, at least one amino acid residue selected from the group consisting of Asp, Glu, Arg, Lys and His; b) substituting, on the surface of the parent subtilase, at least one amino acid residue se- lected from the group consisting of Asp, Glu, Arg, Lys and His with an uncharged amino acid residue; c) optionally repeating steps a) and b) recursively; d) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than b); e) preparing the variant resulting from steps a) - d); f) testing the stability of said variant; and g) optionally repeating steps a
• the above method may be employed. Again, compared to the above method, the only difference being steps a) and b) which, in this case, read: a) identifying, on the surface of the parent subtilase, at least one charged amino acid residue selected from the group consisting of Asp, Glu, Arg, Lys and His; b) substituting, on the surface of the parent subtilase, at least one charged amino acid resi- due identified in step a) with an amino acid residue having an opposite charge.
• Asp may be substituted with Arg, Lys or His;
• Glu may be substituted with Arg, Lys or
• thermostability of a subtilase can be obtained by subjecting the subtilase in question to analysis for secondary structure, identifying residues in the subtilase having dihedral angles ⁇ (phi) and ⁇ (psi) confined to the intervals [-90° ⁇ -40° and -180° ⁇ 180°], preferably the intervals [-90° ⁇ -40° and 120° ⁇ 180°] or [-90° ⁇ -40° and -50° ⁇ 10°] and excluding residues located in regions in which the subtilase is characterized by possessing ⁇ -helical or ⁇ -sheet structure.
• proline residues are generally not compatible with ⁇ -helical and ⁇ -sheet secondary conformations. If a proline residue is not already at the identified position(s), the naturally occurring amino acid residue is substituted with a proline residue, preferably by site directed mutagenesis applied on a gene encoding the subtilase in question.
• TY145 like subtilases proline residues can be introduced at positions 18, 115, 185, 269 and 293. Accordingly, a preferred TY145 variant has one or more of the substitu- tions: Q18P, D115P, V185P, T269P and I293P.
• TY145 a mesophilic-derived enzyme obtained from crystal structure
• TA41 a psychrophilic derived enzyme obtained from modelling
• the higher mobility regions in TA41 compared to TY145 measured by molecular dynamics simulation indicates important regions for the low temperature activity, of the enzyme TA41 which can be transferred to TY145.
• the regions in TA41 are: 16-22 (i.e. 16, 17, 18, 19, 20, 21, 22),
• 40-73 i.e. 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59,
• 118-131 i.e.118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131
• 140-161 i.e.140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161
• 140-161 i.e.140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161
• Regions closest to the active site and the substrate binding site are regarded as preferred in relation to making higher activity at low temperature for TY145: 40-73, and 140-161 , preferably 65-73 and 140-150.
• the regions in TY145 should be modified to be more mobile for example by substitution with small less rigid residues, i.e. residues with smaller side chains (such as Gly, Ala, Ser, Thr or Val), into the TY145 backbone.
• the other regions in TA41 are most interesting for stabilisation of the psychrophilic enzyme. These regions can easily be found in TA39 as well or in other homologous enzymes, also non psychrophilics.
• the regions around the active site and the substrate binding site are the regions most likely involved in the low temperature functionality. Below are suggestions for transferring the low temperature activity of TA41 and homologous sequences to TY145-like sequences and the BPN'-like sequences:
• Savinase is numbered according to BPN'.
• Preferred Savinase variants are V28l, I35V, T71S, I72A, A73L, M175V and T224S.
• Examples of core variants of TY145 are: V31 I, V80A, T79S.
• the alterations of the TY145-like sequences and the BPN'-like sequences can be single mutations or combinations of the suggested mutations.
• the substrate binding site is identified by the residues in contact with a substrate model, such as the CI2 inhibitor.
• a substrate model such as the CI2 inhibitor.
• the 3D structure coordinates of the TY145 subtilase with CI2 bound in the active site can be found in Appendix 1. Without being limited to any theory, it is presently believed that binding between a substrate and an enzyme is supported by favor- able interactions found within a sphere 10 A from the substrate molecule, in particular within a sphere of 6 A from the substrate molecule. Examples of such favorable bonds are hydrogen bonds, strong electrostatic interaction and/or hydrophobic interactions.
• the following residues of the TY145 subtilase (SEQ ID NO:1), are within a distance of 6A from the CI2 inhibitor and thus believed to be involved in interactions with said substrate: 35, 36, 70, 72, 106, 109, 110, 111 , 112, .113, 114, 117, 139, 140, 141 , 142, 143, 144, 145, 147, 150, 167, 168, 169, 170, 171 , 172, 173, 174, 177, 180, 207, 239, 247, 148, 149, 150, 151 and 252.
• the invention consequently further relates to a subtilase, in which either or both residues of any of the Asn-Gly sequence appearing in the amino acid sequence of the parent RP-II protease is/are deleted or substituted with a residue of a different amino acid.
• the Asn and/or Gly residue may, for instance, be substituted with a residue of an amino acid selected from the group consisting of A, Q, S, P, T and Y.
• Asn-Gly sequences can be found in the following positions: B. sphaericus: 198-199, 240-241 TY145: 87-88, 109-110, 199-200 TA41 : 83-84, 198-199 TA39: 88-89, 198-199
• the present invention in this respect thus relates to modifications, such as deletions and substitutions in one or more of these positions in accordance with the principles given above.
• Tyrosines can be found in the following positions:
• TY145 15, 39, 92, 103, 113, 156, 158, 202; 219, 240, 244, 287, 301 , 307, TA41 : 15, 91, 102, 112, 155, 157, 179, 201 , 218, 235, 243,
• the present invention in this respect thus relates to modifications, such as deletions and substitutions in one or more of these positions in accordance with the principles given above.
• Methionines can be found in the following positions: B. sphaericus: 138, 251 ,
• the present invention in this respect thus relates to modifications, such as deletions and substitutions in one or more of these positions in accordance with the principles given above.
• the present invention also encompasses any of the above mentioned subtilase variants in combination with any other modification to the amino acid sequence thereof.
• Especially combinations with other modifications known in the art to provide improved properties to the enzyme are envisaged.
• Such combinations comprise the positions: 222 (improves oxidation stability), 218 (improves thermal stability), substitutions in the Ca 2+ -binding sites stabilizing the enzyme, e.g. position 76, and many other apparent from the prior art (all positions according to BPN' numbering).
• subtilase variant described herein may advantageously be com- bined with one or more modification(s) in any of the positions:
• N76D+V104A or other combinations of the modifications K27R, N76D, S101G, S103A, V104N, V104Y, V104I, V104A, N123S, G159D, A232V, Q236H, Q245R, N248D, N252K,
• T274A in combination with any one or more of the modification(s) mentioned above exhibit improved properties.
• a particular interesting variant is a variant, which, in addition to modifications according to the invention, contains the following substitutions: S101 G+S103A+V104I+G159D+A232V+Q236H+Q245R+N248D+N252K.
• subtilase variants of the main aspect(s) of the invention are preferably combined with one or more modification(s) in any of the positions 129, 131 and 194, preferably as 129K, 131 H and 194P modifications, and most preferably as P129K, P131 H and A194P modifications. Any of those modification(s) are expected to provide a higher expression level of the subtilase variant in the production thereof.
• the subtilase variants i.e. the TY145 and BPN' variants of the present invention may be produced by any known method within the art and the present invention also relates to nucleic acid encoding a subtilase variant of the present invention, a DNA construct comprising said nucleic acid and a host cell comprising said nucleic acid sequence.
• natural occurring proteins may be produced by culturing the organism expressing the protein and subsequently purifying the protein or it may be produced by cloning a nucleic acid, e.g. genomic DNA or cDNA, encoding the protein into an expression vector, introducing said expression vector into a host cell, culturing the host cell and purifying the expressed protein.
• protein variants may be produced by site-directed mutagenesis of a parent protein, introduction into expression vector, host cell etc.
• the parent protein may be cloned from a strain producing the polypeptide or from an expression library, i.e. it may be isolated from genomic DNA or prepared from cDNA, or a combination thereof.
• a parent subtilase, or subtilase or subtilase variant of the invention may be produced by site-directed mutagenesis of a parent protein, introduction into expression vector, host cell etc.
• the parent protein may be cloned from a strain producing the polypeptide or from an expression library, i.e. it may be isolated from genomic DNA or prepared from cDNA, or a combination thereof.
• mutations random and/or site directed
• suitable techniques reference is made to Molecular cloning: A laboratory manual (Sambrook et al. (1989), Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F.
• variants could be constructed by:
• Random Mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in question, or within the whole gene.
• the random mutagenesis of a DNA sequence encoding a parent subtilase may be conven- iently performed by use of any method known in the art.
• a further aspect of the present invention relates to a method for generating a variant of a parent subtilase, wherein the variant exhibits an altered property, such as increased thermostability, increased stability at low pH and at low calcium concentration, relative to the parent subtilase, the method comprising:
• step (b) expressing the mutated DNA sequence obtained in step (a) in a host cell
• Step (c) screening for host cells expressing a subtilase variant which has an altered property relative to the parent subtilase.
• Step (a) of the above method of the invention is preferably performed using doped primers.
• the random mutagenesis may be performed by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis.
• the random mutagenesis may be performed by use of any combination of these mutagenizing agents.
• the mutagenizing agent may, e.g., be one which induces transitions, transversions, inversions, scrambling, deletions, and/or insertions.
• Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS) ; sodium bisulphite, formic acid, and nucleotide analogues.
• UV ultraviolet
• mutagenesis is typically performed by incubating the DNA sequence encoding the parent enzyme to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions for the mutagenesis to take place, and selecting for mutated DNA having the desired properties.
• the oligonucleotide may be doped or spiked with the three non-parent nucleotides during the synthesis of the oligonucleotide at the positions that are to be changed.
• the doping or spiking may be done so that codons for unwanted amino acids are avoided.
• the doped or spiked oligonucleotide can be incorporated into the DNA encoding the subtilase enzyme by any published tech- nique, using, e.g., PCR, LCR or any DNA polymerase and ligase as deemed appropriate.
• the doping is carried out using "constant random doping", in which the percentage of wild-type and modification in each position is predefined.
• the doping may be directed toward a preference for the introduction of certain nucleotides, and thereby a preference for the introduction of one or more specific amino acid residues.
• the doping may be made, e.g., so as to allow for the introduction of 90% wild type and 10% modifications in each position.
• An additional consideration in the choice of a doping scheme is based on genetic as well as protein-structural constraints.
• the doping scheme may be made by using the DOPE program which, inter alia, ensures that introduction of stop codons is avoided (L.J. Jensen et al. Nucleic Acid Research, 26, 697-702 (1998).
• PCR-generated mutagenesis When PCR-generated mutagenesis is used, either a chemically treated or non-treated gene encoding a parent subtilase enzyme is subjected to PCR under conditions that increase the misincorporation of nucleotides (Deshler 1992; Leung et al., Technique, 1 , 1989, pp. 11-15). A mutator strain of £. coli (Fowler et al., Molec. Gen. Genet, 133, 1974, 179-191), S.
• cere- viseae or any other microbial organism may be used for the random mutagenesis of the DNA encoding the subtilase by, e.g., transforming a plasmid containing the parent enzyme into the mutator strain, growing the mutator strain with the plasmid and isolating the mutated plasmid from the mutator strain.
• the mutated plasmid may be subsequently transformed into the ex- pression organism.
• the DNA sequence to be mutagenized may conveniently be present in a genomic or cDNA library prepared from an organism expressing the parent subtilase.
• the DNA sequence may be present on a suitable vector such as a plasmid or a bacteriophage, which as such may be incubated with or otherwise exposed to the mutagenising agent.
• the DNA to be mutagenized may also be present in a host cell either by being integrated in the genome of said cell or by being present on a vector harbored in the cell.
• the DNA to be mutagenized may be in isolated form. It will be understood that the DNA sequence to be subjected to random mutagenesis is preferably a cDNA or a genomic DNA sequence.
• the mutated DNA sequence may be conveniently amplify prior to perform- ing the expression step b) or the screening step c). Such amplification may be performed in accordance with methods known in the art, the presently preferred method being PCR- generated amplification using oligonucleotide primers prepared on the basis of the DNA or amino acid sequence of the parent enzyme. Subsequent to the incubation with or exposure to the mutagenising agent, the mutated DNA is expressed by culturing a suitable host cell carrying the DNA sequence under conditions allowing expression to take place.
• the host cell used for this purpose may be one which has been transformed with the mutated DNA sequence, optionally present on a vector, or one which was carried the DNA sequence encoding the parent enzyme during the mutagenesis treatment.
• suitable host cells are the following: gram positive bacteria such as Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermo- philus, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circu- lans, Bacillus lautus, Bacillus megaterium, Bacillus thuringiensis, Streptomyces lividans or Streptomyces murinus; and gram negative bacteria such as E. coli.
• the mutated DNA sequence may further comprise a DNA sequence encoding functions permitting expression of the mutated DNA sequence.
• the random mutagenesis may be advantageously localised to a part of the parent subtilase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.
• the localised or region-specific, random mutagenesis is conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known in the art.
• the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g., by insertion into a suitable vector, and said part may be subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.
• the random mutagenesis may be carried out by the following steps: 1. Select regions of interest for modification in the parent enzyme
• Suitable dope algorithms for use in step 6 are well known in the art.
• One such algorithm is described by Tomandl, D. et al., 1997, Journal of Computer-Aided Molecular Design 11 :29- 38.
• Another algorithm is DOPE (Jensen, LJ, Andersen, KV, Svendsen, A, and Kretzschmar, T (1998) Nucleic Acids Research 26:697-702).
• a recombinant expression vector comprising a nucleic acid sequence encoding a subtilase variant of the invention may be any vector that may conveniently be subjected to recombinant DNA procedures and which may bring about the expression of the nucleic acid se- quence.
• the choice of vector will often depend on the host cell into which it is to be introduced.
• a suitable vector include a linear or closed circular plasmid or a virus.
• the vector may be an autonomously replicating vector, i.e., a vector which exists as an extra- chromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extra-chromosomal element, a mini chromosome, or an artificial chromosome.
• the vector may contain any means for assuring self-replication.
• Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAM ⁇ l
• Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1.
• the origin of replication may be one having a mutation which makes it function as temperature-sensitive in the host cell (see, e.g., Ehr- lich, 1978, Proceedings of the National Academy of Sciences USA 75:1433).
• the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
• Vectors which are integrated into the genome of the host cell may contain any nucleic acid sequence enabling integration into the genome, in particular it may contain nucleic acid, sequences facilitating integration into the genome by homologous or non-homologous recombination.
• the vector system may be a single vector, e.g. plasmid or virus, or two. or more vectors; e.g. plasmids or virus', which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
• the vector may in particular be an expression vector in which the DNA sequence encoding the subtilase variant of the invention is operably linked to additional segments or control sequences required for transcription of the DNA.
• operably linked indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence encoding the subtilase variant.
• Additional segments or control sequences include a promoter, a leader, a polyadenylation sequence, a propeptide sequence, a signal sequence and a transcription terminator. At a minimum the control sequences include a promoter and transcriptional and translational stop signals.
• the promoter may be any DNA sequence that shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
• suitable promoters for use in bacterial host cells include the promoter of the Ba- cillus subtilis levansucrase gene (sacB), the Bacillus stearothermophilus maltogenic amylase gene (amyM), the Bacillus licheniformis alpha-amylase gene (amyL), the Bacillus amylolique- faciens alpha-amylase gene (amyQ), the Bacillus subtilis alkaline protease gene, or the Bacillus pumilus xylosidase gene, the Bacillus amyloliquefaciens BAN amylase gene, the Bacil- lus licheniformis penicillinase gene (penP), the Bacillus subtilis xylA and xylB genes, and the prokaryotic beta-
• phage Lambda P R or P L promoters examples include the phage Lambda P R or P L promoters or the E. coli lac, trp or tac promoters or the Streptomyces coelicolor agarase gene (dagA). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.
• promoters for use in a filamentous fungal host cell are promoters obtained from the genes encoding Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable al- pha-amylase, Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, Fusahum oxysporum trypsin-like protease (as described in U.S.
• Patent No. 4,288,627 which is incorporated herein by reference
• Particularly preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding Aspergillus niger neutral (-amylase and Aspergillus oryzae triose phosphate isomerase), and glaA promoters.
• Further suitable promoters for use in filamentous fungus host cells are the ADH3 promoter (McKnight et al., The EMBO J. 4 (1985), 2093 - 2099) or the tpiA promoter.
• promoters for use in yeast host cells include promoters from yeast gly- colytic genes (Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 - 12080; Alber and Kawasaki, J. Mol. Appl. Gen. 1 (1982), 419 - 434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al., Nature 304 (1983), 652 - 654) promoters.
• yeast host cells are described by Romanos et al., 1992, Yeast 8:423- 488.
• useful promoters include viral promoters such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus, and bovine papilloma virus (BPV).
• SV40 Simian Virus 40
• RSV Rous sarcoma virus
• BPV bovine papilloma virus
• Suitable promoters for use in mammalian cells are the SV40 promoter (Subra- mani et al., Mol. Cell Biol. 1 (1981), 854 -864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809 - 814) or the adenovirus 2 major late promoter.
• the DNA sequence encoding a subtilase variant of the invention may also, if necessary, be operably connected to a suitable terminator.
• the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
• the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, or a gene encoding resistance to e.g. antibiotics like am- picillin, kanamycin, chloramphenicol, erythromycin, tetracycline, spectinomycine, neomycin, hygromycin, methotrexate, or resistance to heavy metals, virus or herbicides, or which provides for prototrophy or auxotrophs.
• bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, resistance.
• a frequently used mammalian marker is the dihydrofolate reductase gene (DHFR).
• Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1 , and URA3.
• a selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyl- transferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate.
• sC sulfate adenyltransferase
• trpC anthranilate synthase
• glufosinate resistance markers, as- well as equivalents from other species.
• amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomyces hygroscopicus.
• selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.
• a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
• the secretory signal sequence is joined to the DNA sequence encoding the enzyme in the correct reading frame.
• Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the enzyme.
• the secretory signal sequence may be that normally associated with the enzyme or may be from a gene encoding another secreted protein.
• More than one copy of a nucleic acid sequence encoding an enzyme of the present invention may be inserted into the host cell to amplify expression of the nucleic acid sequence.
• Stable amplification of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome using methods well known in the art and selecting for transformants.
• the nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous in the expression of the polypeptide, e.g., an activator (e.g., a trans-acting factor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention.
• an activator e.g., a trans-acting factor
• a chaperone e.g., a chaperone
• processing protease e.g., a factor that is functional in the host cell of choice.
• the nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.
• the DNA sequence encoding a subtilase variant of the present invention may be either homologous or heterologous to the host cell into which it is introduced. If homologous to the host cell, i.e. produced by the host cell in nature, it will typically be operably connected to an- other promoter sequence or, if applicable, another secretory signal sequence and/or terminator sequence than in its natural environment.
• the term "homologous” is intended to include a DNA sequence encoding an enzyme native to the host organism in question.
• heterologous is intended to include: a DNA sequence not expressed by the host cell in nature. Thus, the DNA sequence may be from another organism, or it may be a synthetic. sequence.
• the host cell into which the DNA construct or the recombinant vector of the invention is introduced may be any cell that is capable of producing the present subtilase variants, such as prokaryotes, e.g. bacteria or eukaryotes, such as fungal cells, e.g. yeasts or filamentous fungi, insect cells, plant cells or mammalian cells.
• prokaryotes e.g. bacteria or eukaryotes
• fungal cells e.g. yeasts or filamentous fungi
• insect cells e.g. yeasts or filamentous fungi
• plant cells or mammalian cells examples of bacterial host cells which, on cultivation, are capable of producing the subtilase variants of the invention are gram-positive bacteria such as strains of Bacillus, e.g. strains of B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B.
• amyloliquefaciens B. coagulans, B. circulans, B. lautus, B. megaterium or B. thuringiensis, or strains of Streptomyces, such as S. lividans or S. murinus, or gram-negative bacteria such as Escherichia coli or Pseudomonas sp.
• the transformation of the bacteria may be effected by protoplast transformation, electroporation, conjugation, or by using competent cells in a manner known per se (cf. Sambrook et al., supra).
• the enzyme When expressing the subtilase variant in bacteria such as E. coli, the enzyme may be retained in the cytoplasm, typically as insoluble granules (known as inclusion bodies), or it may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed and the granules are recovered and denatured after which the enzyme is refolded by diluting the denaturing agent. In the latter case, the enzyme may be recovered from the periplasmic space by disrupting the cells, e.g. by sonication or osmotic shock, to release the contents of the periplasmic space and recovering the enzyme.
• the enzyme When expressing the subtilase variant in gram-positive bacteria such as Bacillus or Streptomyces strains, the enzyme may be retained in the cytoplasm, or it may be directed to the extracellular medium by a bacterial secretion sequence. In the latter case, the enzyme may be recovered from the medium as described below.
• yeast cells include cells of a species of Candida, Kluyveromyces, Saccharomyces, Schizosaccharomyces, Pichia, Hansehula, or Yarrowia.
• the yeast host cell is a Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis or Saccharomyces oviformis cell.
• yeast host cells are a Kluyveromyces lactis, Kluyveromyces fragilis, Hansehula polymorpha, Pichia pastoris, Yarrowia lipolytica, Schizosaccharomyces pombe, Ustilgo maylis, Candida maltose, Pichia guillermondii and Pichia methanolio cell (cf. Gleeson et al., J. Gen. Microbiol. 132, 1986, pp. 3459-3465; US 4,882,279 and US 4,879,231).
• yeast Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F , Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980.
• the biology of yeast and manipulation of yeast genetics are well known in the art (see, e.g., Biochemistry and Genetics of Yeast, Bacil, M., Horecker, B.J.; and Stopani, A.O.M.; editors; 2nd edition, 1987; The Yeasts,.
• Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153:163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75:1920.
• filamentous fungal cells include filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra), in particular it may of the a cell of a species of Acremonium, such as A. chrysogenum, Aspergillus, such as A. awamori, A. foetidus, A. japonicus, A. niger, A. nidulans or A. oryzae, Fusa um, such as F. bact di- oides, F. cerealis, F. crookwellense, F. culmorum, F. graminearum, F. graminum, F. hetero- sporum, F.
• a species of Acremonium such as A. chrysogenum, Aspergillus, such as A. awamori, A. foetidus, A. japonicus, A. niger, A. nidulans or A. ory
• insect cells include a Lepidoptera cell line, such as Spodoptera frugiperda cells or Trichoplusia ni cells (cf. US 5,077,214). Culture conditions may suitably be as described in WO 89/01029 or WO 89/01028.Transformation of insect cells and production of heterologous polypeptides therein may be performed as described in US 4,745,051 ; US 4, 775, 624; US 4,879,236; US 5,155,037; US 5,162,222; EP 397,485).
• mammalian cells examples include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS cells, or any number of other immortalized cell lines available, e.g., from the American Type Culture Collection. Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159 (1982), 601 - 621 ; Southern and Berg, J. Mol. Appl. Genet. 1 (1982), 327 - 341 ; Loyter et al., Proc. Natl. Acad. Sci.
• Mammalian cells may be transfected by direct uptake using the calcium phosphate precipitation method of Graham and Van der Eb (1978, Virology 52:546).
• the above mentioned host cells transformed or transfected with a vector comprising a nucleic acid sequence encoding an enzyme of the present invention are typically cultured in a suitable nutrient medium under conditions permitting the production of the desired molecules, after which these are recovered from the cells, or the culture broth.
• the medium used to culture the host cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The media may be prepared using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, More Gene Manipulations in Fungi, Aca- demic Press, CA, 1991).
• the enzymes of the present invention are secreted into the nutrient medium, they may be recovered directly from the medium. If they are not secreted, they may be recovered from cell lysates.
• the enzymes of the present invention may be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chroma- tographic procedures, e.g. ion exchange chromatography, gelfiltration chromatography, affinity chromatography, or the like, dependent on the enzyme in question.
• the enzymes of the invention may be detected using methods known in the art that are specific for these proteins. These detection methods include use of specific antibodies, formation of a product, or disappearance of a substrate. For example, an enzyme assay may be used to determine the activity of the molecule. Procedures for determining various kinds of activ- ity are known in the art.
• the enzymes of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or ex- traction (see, e.g., Protein Purification, J-C Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
• chromatography e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion
• electrophoretic procedures e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or ex- traction
• IEF isoelectric focusing
• differential solubility e.g., ammonium sulfate precipitation
• heterologous host cell When an expression vector comprising a DNA sequence encoding an enzyme of the present invention is transformed/tra ⁇ sfected into a heterologous host cell it is possible to enable heterologous recombinant production of the enzyme.
• An advantage of using a heterologous host cell is that it is possible to make a highly purified enzyme composition, characterized in being free from homologous impurities, which are often present when a protein or peptide is expressed in a homologous host cell.
• homologous impurities mean any impurity (e.g. other polypeptides than the: enzyme of the invention) which originates from the h ⁇ . mologous cell where the enzyme. of the invention is originally obtained from.. . . .
• the enzyme of the invention may be added to and thus become a component of a detergent composition.
• the detergent composition of the invention may for example be formulated as a hand or ma- chine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.
• the invention provides a detergent additive comprising the enzyme of the invention.
• the detergent additive as well as the detergent composition may comprise one or more other enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.
• the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.
• proteases include those of animal, vegetable or microbial origin. Micro- bial origin is preferred. Chemically modified or protein engineered mutants are included.
• the protease may be a serine protease or a metallo protease, preferably an alkaline microbial protease or a trypsin-like protease.
• alkaline proteases are subtilisins, especially those derived from Bacillus, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279).
• trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the Fusarium protease described in WO 89/06270 and WO 94/25583.
• Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101 , 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.
• Preferred commercially available protease enzymes include Alcalase ® , Savinase ® , Primase ® , Duralase ® , Esperase ® , Ovozyme ® and Kannase ® (Novozymes A/S), MaxataseTM, MaxacalTM, MaxapemTM, ProperaseTM, PurafectTM, Purafect OxPTM, FN2TM FN3TM and FN4TM (Genencor International Inc.).
• Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from Humicola (synonym Thermomyces), e.g. from H. lanuginosa (T. lanuginosus) as described in EP 258 068 and EP 305 216 or from H. insolens as described in WO 96/13580, a Pseudomonas lipase, e.g. from P. alcaligenes or P. pseudoalcaligenes (EP 218 272), P. cepacia (EP 331 376), P. stutzeri (GB 1 ,372,034), P.
• lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202.
• Preferred commercially available lipase enzymes include Lipex ® , Lipolase ® and Lipolase Ul- tra ® (Novozymes A/S).
• Amylases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, ⁇ - amylases obtained from Bacillus, e.g. a special strain of B. licheniformis, described in more detail in GB 1 ,296,839.
• Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391 , 408, and 444.
• amylases are DuramylTM, TermamylTM, FungamylTM and BANTM (Novozymes A/S), RapidaseTM and PurastarTM (from Genencor International Inc.). 5
• Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, e.g. the fungal cellulases produced from Humicola insolens, Myceliophthora thermophila and Fusarium ox- 0 ysporum disclosed in US 4,435,307, US 5,648,263, US 5,691 ,178, US 5,776,757 and WO 89/09259.
• cellulases are the alkaline or neutral cellulases having colour care benefits.
• Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940.
• Other examples are cellulase variants such as 5 those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471 , WO 98/12307 and PCT/DK98/00299.
• cellulases include Celluzyme ® and Carezyme ® (Novozymes A/S), ClazinaseTM, ; and Puradax HATM (Genencor International Inc.), and KAC-500(B)TM (Kao Corporation).
• Peroxidases/Oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from Coprinus, e.g. from C. cinereus, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. 5 Commercially available peroxidases include Guardzyme ® (Novozymes A/S).
• the detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes.
• a detergent additive of the invention i.e. a separate additive or a com- 0 bined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc.
• Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.
• Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661 ,452 and may optionally be coated by methods known in the art.
• waxy coating mate- 5 rials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of .1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids.
• Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods.
• Protected enzymes may be prepared according to the method disclosed in EP 238,216.
• the detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid.
• a liquid detergent may be aqueous, typically containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.
• the detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic.
• the surfactants are typically present at a level of from 0.1% to 60% by weight.
• the detergent will usually contain from about 1 % to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.
• an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha
• the detergent When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside; alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoetha- nolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (“glucamides").
• a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside; alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoetha- nolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (“glucamides”).
• the detergent may contain 0-65 % of a detergent builder or complexing agent such as zeo- lite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethyl- enediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).
• a detergent builder or complexing agent such as zeo- lite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethyl- enediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).
• the detergent may comprise one or more polymers.
• examples are carboxymethylcellulose, poly(vinylpyrrolidone), poly (ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.
• the detergent may contain a bleaching system which may comprise a H 2 0 2 source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylethylenediamine or nonanoyloxybenzenesulfonate.
• a bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.
• the enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.
• a polyol such as propylene glycol or glycerol
• a sugar or sugar alcohol lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid
• the detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil- suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hy- drotropes, tarnish inhibitors, or perfumes.
• fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil- suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hy- drotropes, tarnish inhibitors, or perfumes.
• any enzyme in particular the enzyme of the invention, may be added in an amount corresponding to 0.01-200 mg of enzyme protein per liter of wash liqour, preferably 0.05-50 mg of enzyme protein per liter of wash liqour, in particular 0.1-10 mg of enzyme protein per liter of wash liqour.
• the enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202 which is hereby incorporated as reference.
• Standard textile pieces are obtained from EMPA St. Gallen, Lerchfeldstrasse 5, CH-9014 St. Gallen, Switzerland. Especially type EMPA 116 (cotton textile stained with blood, milk and ink) and EMPA 117 (polyester/cotton textile stained with blood, milk and ink).
• the present invention provides a method of producing an isolated enzyme according to the invention, wherein a suitable host cell, which has been transformed with a DNA sequence encoding the enzyme, is cultured under conditions permitting the production of the enzyme, and the resulting enzyme is recovered from the culture.
• the medium used to culture the transformed host cells may be any conventional medium suitable for growing the host cells in question.
• the expressed subtilase may conveniently be secreted into the culture medium and may be recovered there-from by well-known proce- dures including separating the cells from the medium by centrifugation or filtration, precipitating proteinaceous components of the medium by means of a salt such as ammonium sulfate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.
• a library based on Savinase positions V28, I35, T71 , I72, A73, M175 and T224 (BPN' numbering) have been synthesized.
• the library contains exclusively TY145-suggested alterations and covers the introduced mutations V28I,A,L; I35V,A,L; T71S; I72A,G,V; A73L,G; M175V.A; T224S.A introduced in oligopeptides, some of which are doped.
• Doping of nucleotide bases from a desired doping of individual amino acid residues, which is used for the example below, can be calculated as described at page 18 herein. In the attached sequence listing, the doped nucleotides below have been given the nucleo- tide symbols recommended by the WIPO Standard ST25.
• the constructed oligopeptide primers are listed below.
• the primers are named after which positions are subject to modifications, thus 28-35-CN may have alterations in positions 28 and 35, 71-72-73-NC may have alterations in positions 71 , 72 and 73, and so forth.
• the Savinase gene is used as template for five individual PCR reactions under standard PCR conditions (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989) where the oligos are combined as follows: 317 with 28-35-CN, 28-35-NC with 71-72-73-CN (a mixture of 80% (I) 71-72-73-CN, 10% (II) 71-72-73-CN and 10% (III) 71-72-73-CN), 71-72-73-NC with 175-CN (a mixture of 90% (l)175-CN and 10% (ll)175-CN), 175-NC with 224-CN, 224-NC with 139, giving PCR products of 125 bp, 126 bp, 3,12 bp, 165 bp and 158 bp respectively.
• the library is assembled by an additional PCR reaction where the five PCR products are mixed in equal molar amounts. Thereby the library contains a large number of different Savinase variants altered in one or more of the mentioned positions.
• the PCR reaction was assembled using a PTC-200 DNA Engine (MJ Research, Watertown, MA) and the following cycling parameters: 1 cycle of 2 min at 94 °C followed by 25 cycles of 30 sec at 94 °C, 30 sec at 55 °C and 1 min at 68 °C, and 1 cycle of 2 min at 68 °C.
• the library was cloned by PCR multimerization (Shafikhani et al. 1997) into Savinase expression vector psx222 and transformed into a B. subtilis host for expression. Subsequently Savinase variants can be isolated from the library, purified and characterized.
• properties from a BPN' like subtilase could be transferred to TY145 like subtilase by applying a similar procedure.
• the Savinase regions (BPN' numbering) are deleted and the TY145 re- gions (SEQ ID NO:1) are inserted instead.
• regions can be selected for transfer between the psycrophiles TA41/TA39 and BPN' type protease like Savinase, or from TA39/TA41 to TY145 type non-psychrophilic subtilases.
• Savinase variants modified by receiving respectively segments II (Hybrid II), IV (Hybrid IV) or l+ll (Hybrid l+ll) from TY145 were observed to exhibit subtilase activity as determined by the formation of clearing zones on skim milk powder plates.
• the below mentioned highly mobile regions in the TA39 subtilase S39 and the TA41 subti- lase S41 have been selected for transfer to Savinase.
• the Savinase regions (BPN' numbering) are deleted and the S39 regions or S41 regions are inserted instead.
• the S39 and S41 regions are numbered according to Figure 1.
• regions can be selected for transfer between the psychrophiles TA41/TA39 and TY145 type non-psychrophilic subtilases.
• Savinase variant V104S is used as acceptor for the S39 segment II.
• Savinase variants modified by receiving respectively segments I or II from S39 were observed to have subtilase activity against the substrate suc-AAPF-pNA (Suc-Ala-Ala-Pro-Phe- pNA).
• the subtilase activity was determined in a temperature profile assay where specific activities i.e. micromole substrate per minute per mg enzyme against before mentioned substrates, were determined at every 5 degrees Celsius. The measurements were done in a Tris-base buffer pH 9.
• subtilase activity in suc-AAPF-pNA 100 uL 1.56 mM Suc-Ala-Ala-Pro-Phe-pNA in 0.1 M Tris was added to 100 uL Tris-base, pH 9.0 buffer and 20 uL enzyme.
• the devel- opment of the degradation product pNA paranitrophenol was measured as initial velocities at 405 nm on an Elisa Reader for 1 minute.
• the Savinase variant with segment I substituted had less specific activity against suc-AAPF- pNA compared to Savinase, whereas the Savinase variant with segment II substituted had more than 2 times higher specific activity against suc-AAPF-pNA than Savinase.
• an AMSA-test (performed like described in Example 5 herein) the wash performance was shown to be preserved in Savinase variant with segment II compared to Savinase.
• SEGMENT VIII S41 GTNFTD, positions 55-62 (SEQ ID NO: 40) Savinase VPG*EPST, positions 51-58 (SEQ ID NO: 41)
• Savinase variants were constructed with the following segments from S41 : Segment X; Segments IX and X; Segments VIII and X; and Segments X and XI. All four Savinase variants showed subtilase activity on skim milk plates.
• AMSA wash tests were performed on variants with Segment X and Segments X and XI like described in Example 5 herein.
• the assay was conducted under the experimental conditions specified below:
• the wash performance score (described in Example 5 herein) of the Savinase variants with Segment X and Segments X and XI was S (1) indicating an improved wash performance compared to Savinase.
• HCIC Hydrophobic Charge Induction Chromatography
• 4-MEP 4-Mercapto-Ethyl-Pyridine
• Beads of the cellulose matrix sized 80-100 ⁇ m are mixed with a media containing yeast and the transformed B. subtilis capable of secreting the subtilisin variants and incubated at pH 9.5 in Unifilter ® microplates.
• the concentration of the purified subtilisin enzyme variants is assessed by active site titration (AST).
• the purified enzyme is incubated with the high affinity inhibitor CI-2A at different concentrations to inhibit a varying amount of the active sites.
• the protease and inhibitor binds to each other at a 1 :1 ratio and accordingly the enzyme concentration can be directly related to the concentration of inhibitor, at which all protease is inactive.
• a substrate suc-AAPF-pNA 0.6 mM Suc-Ala-Ala-Pro-Phe-pNA in Tris/HCI buffer
• the degradation product pNA paranitrophenol
• Wash performance of detergent compositions comprising modified enzymes Wash performance of detergent compositions comprising enzyme hybrids or enzyme variants of the present is tested at low washing temperature.
• the Savinase variant Hybrid IV of Example 2 was tested for washing performance in two different assays; a microlitre scale assay (AMSA) and a millilitre scale assay (Mini wash).
• AMSA microlitre scale assay
• Mini wash millilitre scale assay
• AMSA Automatic Mechanical Stress Assay
• the performance of the enzyme variant is measured as the brightness of the colour of the textile samples washed with that specific enzyme variant. Brightness can also be expressed as the intensity of the light reflected from the textile sample when luminated with white light. When the textile is stained the intensity of the reflected light is lower, than that of a clean textile. Therefore the intensity of the reflected light can be used to measure wash performance of an enzyme variant.
• Colour measurements are made with a professional flatbed scanner (PFU DL2400pr ⁇ ), which is used to capture an image of the washed textile samples.
• the scans are made with a resolution of 200 dpi and with an output colour dept of 24 bits.
• the scanner is frequently calibrated with a Kodak reflective IT8 target.
• a special designed software application is used (Novozymes Color Vector Analyzer).
• the program retrieves the 24 bit pixel values from the image and converts them into values for red, green and blue (RGB).
• the intensity value (Int) is calculated by adding the RGB values together as vectors and then taking the length of the resulting vector:
• Int(v) is the light intensity value of textile surface washed with enzyme variant and lnt(r) is the light intensity value of textile surface washed with the reference enzyme subtilisin
• Performance Scores are summing up the performances (P) of the tested enzyme variants as: S (2) which indicates that the variant performs better than the reference at all three concentrations (5, 10 and 30 nM) and
• the millilitre scale wash performance assay was conducted under the following conditions:
• the measurement of remission from the test material was done at 460 nm using a Zeiss MCS 521 VIS spectrophotometer. The measurements were done according to the manufacturer's protocol.
• REMARK REFINEMENT REFINEMENT .
• ATOM 236 N ASN A 16 13. .075 33 .432 21, .780 1. .00 17, .21 N
• ATOM 238 CA ASN A 16 12. .534 34 .334 22, .811 1. .00 17 .53 C
• ATOM 260 C ASP A 17 8, .937 35 .412 19, .778 1, .00 19 .80 C
• ATOM 382 CA GLY A 26 24.296 29.380 10.938 1 1. . ,0000 1 155 . .4444 C
• ATOM 422 C ILE A 29 28, .143 24 .586 9. .459 1, .00 14. .30 c
• ATOM 462 N ALA A 32 26 .129 17 .789 11. .737 1, .00 14, .62 N
• ATOM 471 O ALA A 32 25, .056 15, .556 13. .393 1, .00 12, .55 O
• ATOM 507 N ASP A 35 21, .571 9, .765 12. .490 1. .00 11, .34 N
• ATOM 518 O ASP A 35 20 .470 7. .623 11, .250 1, .00 12 .33 o
• ATOM 558 CA TYR A 39 15. ,046 13. .247 3. 214 1. ,00 19. ,90 C
• ATOM 604 CA HIS A 42 12 .245 17 .917 1, .419 1, .00 21, .28 C
• ATOM 670 N ALA A 46 16 .104 21 .400 1 .079 1 .00 22 .51 N
• ATOM 678 C ALA A 46 17. 880 22. .199 -0. 244 1. 00 20. ,28 c
• ATOM 682 CA GLY A 47 20. ,217 22. .320 -0. ,968 1. ,00 21. .84 C
• ATOM 703 N ALA A 49 22. ,035 19, .670 2. ,285 1. ,00 20. .96 N
• ATOM 705 CA ALA A 49 22. ,951 18, .532 2. ,483 1. ,00 22. ,38 C
• ATOM 730 CA GLN A 51 27, .273 15 .186 2, .847 1. .00 18, .38 C
• ATOM 833 CD GLN A 57 23, .366 0, .800 2. .117 1. .00 36, .31 c
• ATOM 842 CA SER A 58 26, .798 -4. .440 4. .371 1. .00 34, .96 C
• ATOM 853 CA ASN A 59 29, .409 -2 .054 3, .003 1. .00 38, .41 C
• ATOM 878 O PRO A 60 30 .266 2 .188 6 .749 1 .00 34 .22 O
• ATOM 968 N ASP A 68 16. .070 8, .278 4. .623 1. .00 17 .54 N
• ATOM 982 CA ARG A 69 12. .427 5, .549 5. .858 1. .00 20, .20 C
• ATOM 984 CB ARG A 69 12. .665 4, .106 5. .357 1. .00 20, .57 C
• ATOM 1020 O GLN A 70 9 .502 7. .745 10, .177 1, .00 18 .53 O
• ATOM 1036 NDl HIS A 72 15, .356 10. .264 15. ,228 1. .00 11. .65 N
• ATOM 1048 CA GLY A 73 16, .140 11, .851 11. .227 1. .00 13, .67 C
• ATOM 1069 CA HIS A 75 12 .345 15 .653 11, ,803 1. .00 13, .53 C

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Enzymes And Modification Thereof (AREA)
• Detergent Compositions (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (9)

Applications Claiming Priority (6)

Related Child Applications (3)

Publications (2)

Family

ID=32830227

Family Applications (1)

Country Status (2)

Cited By (161)

Citations (1)

• 2004
  • 2004-01-30 EP EP04706617A patent/EP1590454A2/de not_active Ceased
  • 2004-01-30 WO PCT/DK2004/000066 patent/WO2004067737A2/en active Application Filing

Patent Citations (1)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events